Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cedric Francois

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Plastic and Reconstructive Surgery|August 26, 2006
Investigation of risk acceptance in facial transplantationJohn H Barker, Allen Furr, Michael Cunningham, et al.
The New England Journal of Medicine|March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Jeff Szer, Ilene Weitz, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Immunotherapy|January 17, 2025
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studiesJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
Lancet (London, England)|October 21, 2023
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trialsJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
The New England Journal of Medicine|December 3, 2025
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGNFadi Fakhouri, Andrew S Bomback, Gema Ariceta, et al.
Nature Biotechnology|March 8, 2017
US immigration order strikes against biotechJeremy M Levin, Steven H Holtzman, John Maraganore, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Plastic and Reconstructive Surgery|August 26, 2006
Investigation of risk acceptance in facial transplantationJohn H Barker, Allen Furr, Michael Cunningham, et al.
The New England Journal of Medicine|March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Jeff Szer, Ilene Weitz, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Immunotherapy|January 17, 2025
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studiesJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
Lancet (London, England)|October 21, 2023
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trialsJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
The New England Journal of Medicine|December 3, 2025
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGNFadi Fakhouri, Andrew S Bomback, Gema Ariceta, et al.
Nature Biotechnology|March 8, 2017
US immigration order strikes against biotechJeremy M Levin, Steven H Holtzman, John Maraganore, et al.
Pageof 2